bioRxivImmunologyPreprint
Rare SH2B3 coding variants identified in lupus patients impair B cell tolerance and predispose to autoimmunity
Y. Zhang, R. Morris, A. M. D. Lorenzo, X. Meng, N. J. Kershaw, P. Kiridena, G. J. Brown, G. Burgio, J. Y. Cappello, Q. Shen, H. Wang, C. M. Turnbull, T. Lea-Henry, M. Stanley, Z. Yu, F. Ballard, A. Chuah, J. C. Lee, A.-M. Hatch, A. P. Headley, P. Trnka, D. Mallon, J. T. Fletcher, G. D. Walters, M. Sestan, , J. I. Ellyard
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease, with a clear genetic component. While most SLE patients carry rare gene variants in lupus risk genes, little is known about their contribution to disease pathogenesis. Amongst them, SH2B3 - a negative regulator of cytokine and growth factor receptor signaling - harbors rare coding variants in over 5% of SLE patients. Here we show that unlike the variant found exclusively in healthy controls, most SH2B3 rare variants found in lupus patients are predominantly hypomorphic alleles. Generation of two mouse lines carrying variants orthologous to those found in patients revealed SH2B3 is important to limit the numbers of immature and transitional B cells. Furthermore, hypomorphic SH2B3 was shown to impair negative selection of immature/transitional self-reactive B cells and accelerate autoimmunity in sensitized mice, at least in part due to increased IL-4R signaling and BAFF-R expression. This work identifies a previously unappreciated role for SH2B3 in human B cell tolerance and lupus risk. SummaryZhang et al. reveal a role for hypomorphic SH2B3 in lupus risk. The study shows rare and damaging variants identified in lupus patients enable breach of B cell immune tolerance checkpoints and suggests involvement for dysregulated IL-4R signaling and BAFF-R expression.
- organism: human
- organism: mouse
- assay: DNA methylation
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dysregulation of anti-Ro60 B cell autoreactivity in systemic lupus erythematosus
Oindrila Rahaman, Carlos Eduardo Castrillon, … Igñacio Sanz·bioRxiv·May 13, 2026
- STAT3-mediated allelic imbalance of novel genetic variant rs1047643 and B cell specific super-enhancer in association with systemic lupus erythematosus
Yanfeng Zhang, Kenneth Day, Devin M. Absher·eLifePeer-reviewed·Feb 21, 2022
- ARID3a-Expressing Naive B Cells in SLE have an Activated Phenotype and Transiently Express Surface CD68
Joshua W. Garton, James Randolph Sanders Hocker, … Carol F. Webb·bioRxiv·Jul 16, 2026
- SELECTION OF ANTI-NUCLEAR ANTIGEN (ANA) REACTIVE B CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS.
Yemil Atisha‐Fregoso, Wenzhao Meng, … Betty Diamond·bioRxiv·Jan 8, 2025
- IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodies
Hugo J. van Dooren, Yemil Atisha‐Fregoso, … Jolien Suurmond·Journal of AutoimmunityPeer-reviewed·May 25, 2025
- Ezh2 knockout in B cells impairs plasmablast differentiation and ameliorates lupus-like disease in MRL/lpr mice
X. Zheng, M. G. Dozmorov, … A. H. Sawalha·bioRxiv·Jul 21, 2022